Alaska Department of Revenue Decreases Shareholdings in Certara, (NASDAQ:CERT)
April 1, 2023
Trending News 🌥️
The Alaska Department of Revenue has recently announced that it has decreased its ownership in Certara ($NASDAQ:CERT), Inc. (NASDAQ:CERT). Certara is a leading global software and consulting company that provides integrated solutions to improve drug development and regulatory submission process. Certara’s main products and services include its Simcyp Simulator, Phoenix WinNonlin software and its Certara Regulatory Consulting. The company also offers services in the areas of pharmacometrics and pharmacokinetics, biostatistics and clinical trial simulation to support its customers’ drug-development strategies.
In addition, Certara also provides strategic consulting services to support clients’ regulatory submissions. The Alaska Department of Revenue’s decision to decrease its ownership in Certara is likely due to a lack of confidence in the company’s future prospects and performance.
Market Price
On Monday, CERTARA stock opened at $24.0 and closed at $23.8, an increase of 0.8% from its last closing price of $23.6. This decrease in the department’s shareholding is likely to have a minimal impact on the stock’s overall performance. However, the announcement has created some uncertainty in the market and investors are advised to approach the stock with caution. certara,-(nasdaq:cert)”>Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Certara. certara,-(nasdaq:cert)”>More…
| Total Revenues | Net Income | Net Margin |
| 335.64 | 14.73 | 4.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Certara. certara,-(nasdaq:cert)”>More…
| Operations | Investing | Financing |
| 92.54 | -27.84 | -7.36 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Certara. certara,-(nasdaq:cert)”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.57k | 493.26 | 6.77 |
Key Ratios Snapshot
Some of the financial key ratios for Certara are shown below. certara,-(nasdaq:cert)”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.2% | 18.4% | 10.9% |
| FCF Margin | ROE | ROA |
| 23.8% | 2.1% | 1.5% |
Analysis
GoodWhale has conducted an analysis of CERTARA’s wellbeing and found that it has a high health score of 8/10 considering its cash flows and debt, is capable of paying off debt and funding future operations. The Star Chart showed that CERTARA is strong in growth, medium in profitability and weak in asset, dividend. Based on this, we concluded that CERTARA has achieved a high revenue or earnings growth, but is considered less stable due to lower profitability. Therefore, we classify CERTARA as a ‘cheetah’, a type of company that appeals to a particular type of investor. Investors looking for a higher risk-reward profile may be interested in CERTARA, as well as those who are comfortable with the associated risk of investing in a less stable company. certara,-(nasdaq:cert)”>More…
Peers
The competition in the genomics market is heating up as Certara Inc goes up against 10x Genomics Inc, Cambridge Cognition Holdings PLC, and Schrodinger Inc. All four companies are vying for a piece of the market share in this rapidly growing industry. So far, Certara Inc has been the most successful, but the other three are not far behind.
– 10x Genomics Inc ($NASDAQ:TXG)
As of 2022, 10x Genomics Inc has a market cap of 2.93B. The company’s Return on Equity for that year was -10.81%. 10x Genomics is a company that provides sequencing and gene editing services.
– Cambridge Cognition Holdings PLC ($LSE:COG)
Cambridge Cognition Holdings PLC is a neuropsychological testing company. The company develops and commercializes cognitive tests used by clinicians and researchers to assess brain function in patients with neurological and psychiatric disorders. Cambridge Cognition’s tests are used in clinical trials to measure the efficacy of new treatments and to screen patients for clinical studies. The company’s products are also used by pharmaceutical companies to support marketing claims for cognitive enhancing drugs.
– Schrodinger Inc ($NASDAQ:SDGR)
Schrodinger Inc is a publicly traded company with a market capitalization of 1.55 billion as of 2022. The company has a return on equity of -15.16%. Schrodinger is a provider of advanced molecular simulations and enterprise software solutions. The company’s flagship product, Maestro, is a molecular modeling and simulation software platform used by scientists to predict the behavior of complex molecules and materials.
Summary
Investors in Certara, Inc. (NASDAQ: CERT) have received a boost as the State of Alaska Department of Revenue recently reduced its stake in the life sciences software and informatics company. Analysts indicate that this could be a sign of confidence in the company and its prospects. The sale could be seen as a positive indication of Certara’s financial health and earnings potential. Analysts point out the company’s strong fundamentals, including its revenue growth, varied product offering, and expanding customer base.
Furthermore, Certara has implemented various cost-saving initiatives to help maintain profits. Overall, analysts believe that CERT is a good investment opportunity and is well-positioned to continue growing its business.
Related Posts
Recent Posts
